CD4 and non-small cell lung carcinoma: These findings are in line with the results described by Wang et al. [29], who reported that lentinan, a β-1,3-branched β-1,6-D-glucan, increased the number of CD3+CD4+ and CD3+CD8+ T cells in patients with non-small cell lung cancer treated with chemotherapy.